Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

In vitro Biological Characterization of IFN-β-1a major Glycoforms.
TNF receptor 1 genetic risk mirrors outcome of anti-TNF therapy in multiple sclerosis.
[Controlled research on multiple sclerosis treated with electroacupuncture and acupoint injection].
Delta 9-tetrahydrocannabinol: a novel treatment for experimental autoimmune encephalomyelitis.
Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies.
Safety and Tolerability Study of MEDI-551, a B-cell Depleting Agent, to Treat Relapsing Forms of Multiple Sclerosis
Transverse myelitis associated with heroin and cannabis abuse: a new issue from the past.
Biologics at Novartis
Teva and Takeda announce agreement for glatiramer acetate for multiple sclerosis treatment in Japan
Severe haematological complications during treatment with natalizumab.
Identifying autoantigens in demyelinating diseases: valuable clues to diagnosis and treatment?
[Vitamin D for prevention of diseases?].
Plasma exchange in severe attacks of neuromyelitis optica.
Evaluation of Dalfampridine Extended Release 5 and 10 mg in Multiple Sclerosis: A Randomized Controlled Trial.
[Cyclophosphamide pulse therapy effective for childhood-onset refractory multiple sclerosis: a case report].
The contemporary spectrum of multiple sclerosis misdiagnosis: A multicenter study.
Modulation of Sox10, HIF-1α, Survivin, and YAP by Minocycline in the Treatment of Neurodevelopmental Handicaps following Hypoxic Insult.
On dihydroorotate dehydrogenases, their inhibitors and uses.
Monocytes and CD4+ T cells contribution to the under-expression of NR4A2 and TNFAIP3 genes in patients with multiple sclerosis.
Molecular targets of FTY720 (fingolimod).
Dried Blood Spot Methodology in Combination With Liquid Chromatography/Tandem Mass Spectrometry Facilitates the Monitoring of Teriflunomide.
Brain parenchymal damage in neuromyelitis optica spectrum disorder - A multimodal MRI study.
Norovirus-related chronic diarrhea in a patient treated with alemtuzumab for chronic lymphocytic leukemia.
Endogenous retroviruses and multiple sclerosis--new pieces to the puzzle.
Anti-phospholipid antibodies are associated with response to interferon-beta1a treatment in MS: results from a 3-year longitudinal study.

Pages